Stocks

Merck Licenses KRAS G12D Inhibitor SPR2015 for $400M Upfront

Guavy AI Editorial Team Published September 29, 2026

Instruments

MRK

Pharmaceutical giant Merck has entered into an exclusive global license agreement with SciBrunch Therapeutics Co., Ltd. for the investigational preclinical oral KRAS G12D inhibitor SPR2015.

The deal is worth $400 million upfront and could reach a total of $2.13 billion, including milestone payments related to development, commercialization, and other activities across multiple indications.

SPR2015 has shown promise in preclinical data, demonstrating nanomolar antiproliferative activities in various KRAS G12D-mutant cell lines and antitumor efficacy as a monotherapy in multiple in vivo cell-derived and patient-derived xenograft models.

SciBrunch Therapeutics is a clinical-stage biotech company founded in late 2024 with a focus on small molecule oncology therapeutics, while BofA Securities acted as exclusive financial advisor to the company in connection with the transaction.

Merck Licenses KRAS G12D Inhibitor SPR2015 for $400M Upfront

JPMorgan Unveils Dual-Directional Structured Note Linked to S&P 500 Index

Meta Stock Price Triggers Split Speculation as Dow Inclusion Looms

Caterpillar Inc.'s Neutral Readings May Moderate Long-Term Outlook